Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Laga

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
The Lancet. Global Health|August 9, 2014
Effect of HIV prevention in key populations: evidence accumulates, time to implementMarie Laga
Lancet (London, England)|March 20, 2012
Avahan and impact assessmentMarie Laga, Rob Moodie
AIDS (London, England)|June 19, 2012
Prevention of sexual transmission of HIV: real results, science progressing, societies remaining behindMarie Laga, Peter Piot
BMC Public Health|March 2, 2012
Evaluating AVAHAN's design, implementation and impact: lessons learned for the HIV Prevention CommunityMarie Laga, Bea Vuylsteke
AIDS (London, England)|November 1, 2021
Measuring progress in the roll-out of pre-exposure prophylaxis: from counting what we know, to knowing what to countJef Vanhamel, Marie Laga
AIDS (London, England)|June 19, 2012
Epidemiological research in the HIV field: towards understanding what we do not knowAnne Buvé, Marie Laga
The Lancet. Global Health|August 9, 2014
Lifelong ART for 20 million people in sub-Saharan Africa: communities will be key for successTom Decroo, Nathan Ford, Marie Laga
AIDS (London, England)|March 4, 2006
The real challenges for scaling up ART in sub-Saharan AfricaWim Van Damme, Katharina Kober, Marie Laga
AIDS (London, England)|October 21, 2003
The evaluation of the HIV/AIDS drug access initiatives in Côte d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in AfricaDavid Katzenstein, Marie Laga, Jean-Paul Moatti
AIDS (London, England)|February 9, 2012
Evaluating HIV prevention effectiveness: the perfect as the enemy of the goodMarie Laga, Deborah Rugg, Greet Peersman, et al.
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
The Lancet. Global Health|August 9, 2014
Effect of HIV prevention in key populations: evidence accumulates, time to implementMarie Laga
Lancet (London, England)|March 20, 2012
Avahan and impact assessmentMarie Laga, Rob Moodie
AIDS (London, England)|June 19, 2012
Prevention of sexual transmission of HIV: real results, science progressing, societies remaining behindMarie Laga, Peter Piot
BMC Public Health|March 2, 2012
Evaluating AVAHAN's design, implementation and impact: lessons learned for the HIV Prevention CommunityMarie Laga, Bea Vuylsteke
AIDS (London, England)|November 1, 2021
Measuring progress in the roll-out of pre-exposure prophylaxis: from counting what we know, to knowing what to countJef Vanhamel, Marie Laga
AIDS (London, England)|June 19, 2012
Epidemiological research in the HIV field: towards understanding what we do not knowAnne Buvé, Marie Laga
The Lancet. Global Health|August 9, 2014
Lifelong ART for 20 million people in sub-Saharan Africa: communities will be key for successTom Decroo, Nathan Ford, Marie Laga
AIDS (London, England)|March 4, 2006
The real challenges for scaling up ART in sub-Saharan AfricaWim Van Damme, Katharina Kober, Marie Laga
AIDS (London, England)|October 21, 2003
The evaluation of the HIV/AIDS drug access initiatives in Côte d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in AfricaDavid Katzenstein, Marie Laga, Jean-Paul Moatti
AIDS (London, England)|February 9, 2012
Evaluating HIV prevention effectiveness: the perfect as the enemy of the goodMarie Laga, Deborah Rugg, Greet Peersman, et al.
Pageof 9